NewsBite

Rich list names hurt by cruel April for biotech stocks

In April almost $1 billion was wiped from the combined market value of four well-regarded companies: Acrux, Mesoblast, QrXPharma and Prana Biotechnology, dragging down equally well known names such as Waislitz and Liberman.

Jessica Gardner
Jessica GardnerDeputy editor - News
Updated

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

The portfolios of some of Australia’s richest investors have been battered by the terrible start to the year experienced by biotechnology stocks.

In April, almost $1 billion was wiped from the combined market value of four companies, Acrux , Mesoblast , QrXPharma and Prana Biotechnology , dragging down equally well known names like Waislitz, Liberman, Smorgon and Walker.

Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Read More

Latest In Healthcare & fitness

Fetching latest articles

Most Viewed In Companies

    Original URL: https://www.afr.com/companies/healthcare-and-fitness/rich-list-names-hurt-by-cruel-april-for-biotech-stocks-20140505-iu0eh